RT @GilardiMara: Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas https://t.co/WhJIcAsLdR
RT @GilardiMara: Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas https://t.co/WhJIcAsLdR
RT @imsmd: Mollie Leoni @kuraoncology describes the farnesyltransferase inhibitor (FTI) tipifarnib which showed preclinical activity in HRA…
RT @imsmd: Mollie Leoni @kuraoncology describes the farnesyltransferase inhibitor (FTI) tipifarnib which showed preclinical activity in HRA…
Mollie Leoni @kuraoncology describes the farnesyltransferase inhibitor (FTI) tipifarnib which showed preclinical activity in HRASm #HNSCC (see one of the cited papers: https://t.co/Z5vJB3H3Hp @RDavis_PhD) and is now being clinically evaluated in the RUN-IN
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas https://t.co/WhJIcAsLdR
RT @MCT_AACR: Gilardi et al find that HRAS is a druggable oncogene in head and neck squamous cell carcinoma through farnesyltransferase inh…
DRUG TARGETS, HRAS [1/3]: targeting HRAS-mutant tumours with the farnesyltransferase inhibitor tipifarnib has been around for sometime with mixed results. New data suggest efficacy for tipifarnib in preclinical xenograft models of head and neck cancer. htt
Gilardi et al find that HRAS is a druggable oncogene in head and neck squamous cell carcinoma (#HNSCC ) through farnesyltransferase inhibition by #tipifarnib thereby identifying a precision therapeutic option for HNSCC w/HRAS mutations. @UCSDHealth https
Gilardi et al find that HRAS is a druggable oncogene in head and neck squamous cell carcinoma through farnesyltransferase inhibition by #tipifarnib, thereby identifying a precision therapeutic option for #HNSCC with HRAS mutations. @UCSDHealth https://t.co
RT @UCSDBMS: New work from the @SilvioGutkind and more show that mutant HRAS is a key recurring mutation in many head / neck cancers, but i…
RT @kuraoncology: Check out the recent publication in @MCT_AACR that reports on the mechanism of action of tipifarnib in #HNSCC. @UCSanDieg…
RT @kuraoncology: Check out the recent publication in @MCT_AACR that reports on the mechanism of action of tipifarnib in #HNSCC. @UCSanDieg…
New work from the @SilvioGutkind and more show that mutant HRAS is a key recurring mutation in many head / neck cancers, but it is a druggable target. Press release: https://t.co/EcPttcyIkM Paper: https://t.co/CcZEoL9Kyy
RT @kuraoncology: Check out the recent publication in @MCT_AACR that reports on the mechanism of action of tipifarnib in #HNSCC. @UCSanDieg…
Check out the recent publication in @MCT_AACR that reports on the mechanism of action of tipifarnib in #HNSCC. @UCSanDiego @SilvioGutkind [https://t.co/y6rLRx6HMU] https://t.co/tESzwXLilX